300765.SHE CSPC Innovation Pharmaceutical Co Ltd Class A
- Market cap
- CNY 41.3B
- P/E
- 41.4x
- P/B
- 11.69x
- ROE
- 41.5%
- Dividend yield
- 0.09%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300765.SHE undervalued?
Graham numberThe Graham number of CSPC Innovation Pharmaceutical Co Ltd Class A cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CSPC Innovation Pharmaceutical Co Ltd Class A fundamental analysis
No fundamental analysis for CSPC Innovation Pharmaceutical Co Ltd Class A yet.
CSPC Innovation Pharmaceutical Co Ltd Class A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CSPC Innovation Pharmaceutical Co Ltd Class A
CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials in China and internationally. The company offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dyphylline, theobromine, pentoxifylline, and doxofylline; and health food products, such as Guoweikang Vitamin C tablets, Guoweikang B vitamin lozenges, etc. It …
Full company profileCSPC Innovation Pharmaceutical Co Ltd Class A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CSPC Innovation Pharmaceutical Co Ltd Class A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 890M | 1.03B | 1.24B | 1.26B | 1.32B | 1.85B | 2.63B | 2.54B | 1.98B | 2.15B | 5.30B |
| Gross Profit | 420M | 503M | 607M | 643M | 732M | 807M | 1.13B | 1.16B | 826M | 688M | 3.78B |
| Operating Income | 248M | 241M | 277M | 333M | 360M | 487M | 856M | 262M | -218M | -626M | 2.08B |
| EBITDA | 278M | 277M | 324M | 384M | 419M | 550M | 925M | 418M | 1.76M | -403M | 2.05B |
| Net Income | 207M | 195M | 224M | 273M | 300M | 393M | 726M | 434M | 53.7M | -241M | 1.61B |
| EPS | 0.23 | 0.22 | 0.25 | 0.25 | 0.25 | 0.29 | 0.54 | 0.31 | 0.04 | -0.17 | 1.15 |
| Balance Sheet | |||||||||||
| Total Assets | 969M | 1.13B | 1.39B | 2.85B | 2.96B | 3.74B | 4.58B | 7.47B | 6.02B | 6.28B | 8.21B |
| Total Liabilities | 397M | 362M | 391M | 437M | 270M | 444M | 640M | 1.99B | 1.53B | 3.48B | 3.91B |
| Shareholders' Equity | 572M | 767M | 991M | 2.41B | 2.68B | 3.29B | 3.94B | 5.28B | 3.73B | 2.67B | 3.89B |
| Cash & Short-term Investments | 151M | 68.2M | 156M | 1.44B | 1.46B | 1.66B | 2.20B | 3.77B | 1.34B | 1.16B | 1.03B |
| Total Debt | 120M | 95.7M | 20.6M | 12.5M | 841K | 841K | 19.8M | 841K | 93.7M | 4.87M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 137M | 1.30M | 160M | 315M | 349M | 292M | 641M | 927M | -1.24B | -196M | - |
| Capital Expenditure | 148M | 42.8M | 59.0M | 106M | 118M | 66.9M | 114M | 95.7M | 478M | 568M | 426M |
| Free Cash Flow | -10.5M | -41.5M | 101M | 209M | 231M | 104M | 527M | 832M | -1.71B | -764M | 3.14B |
| Ratios | |||||||||||
| ROE | 36.1% | 25.4% | 22.6% | 11.4% | 11.2% | 12.0% | 18.5% | 8.2% | 1.4% | -9.0% | 41.5% |
| ROA | 21.3% | 17.3% | 16.1% | 9.6% | 10.1% | 10.5% | 15.8% | 5.8% | 0.9% | -3.8% | 19.7% |
| Net Profit Margin | 23.2% | 18.9% | 18.1% | 21.7% | 22.8% | 21.3% | 27.7% | 17.1% | 2.7% | -11.2% | 30.4% |
| Debt to Equity | 0.21x | 0.12x | 0.02x | 0.01x | 0.00x | 0.00x | 0.01x | 0.00x | 0.03x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CSPC Innovation Pharmaceutical Co Ltd Class A dividends
- Dividend yield
- 0.09%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 36.4M | 0.03 | - |
| 2024 | CNY 374M | 0.27 | 696.4% |
| 2023 | CNY 97.8M | 0.07 | 22.5% |
| 2022 | CNY 82.1M | 0.06 | 11.3% |
| 2021 | CNY 42.0M | 0.03 | 10.7% |
| 2020 | CNY 28.0M | 0.02 | 9.3% |
| 2019 | CNY 1.50M | 0.00 | 0.5% |
| 2018 | CNY 3.39M | 0.00 | 1.5% |
| 2017 | CNY 24.8M | 0.03 | 12.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Apr 25, 2024.
Who owns CSPC Innovation Pharmaceutical Co Ltd Class A
- Insiders 75.45%
- Institutions 6.75%
- Public & others 17.80%
- Shares outstanding 1.40B
- Free float 344M
CSPC Innovation Pharmaceutical Co Ltd Class A company profile
- Company name
- CSPC Innovation Pharmaceutical Co Ltd Class A
- Ticker
- 300765.SHE
- ISIN
- CNE100003K04
- Exchange
- Shenzhen Stock Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 2,369
- Fiscal year end
- December
- Address
- No. 62 Zhangju Road, Shijiazhuang, China, 051430
- Phone
- 86 311 8540 8700
- Website
- xnwpharma.net
About CSPC Innovation Pharmaceutical Co Ltd Class A
CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials in China and internationally. The company offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dyphylline, theobromine, pentoxifylline, and doxofylline; and health food products, such as Guoweikang Vitamin C tablets, Guoweikang B vitamin lozenges, etc. It also provides technology transfer and technical consulting services of biotechnology. The company was founded in 2006 and is headquartered in Shijiazhuang, China. CSPC Innovation Pharmaceutical Co., Ltd. is a subsidiary of CSPC NBP Pharmaceutical Co., Ltd.
CSPC Innovation Pharmaceutical Co Ltd Class A management
5- Dr. Bing YaoExecutive Chairman · born 1977
- Mr. Long DaiGM, CFO & Director · born 1992
- Ms. Wen XuSecretary & Director · born 1990
- Dr. Xiwu HuiDeputy General Manager · born 1986
- Hong Chao LiHead of Accounting